Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234

Limited treatment options exist to combat infections caused by multidrug-resistant (MDR) Gram-negative bacteria possessing broad-spectrum β-lactamases. The design of novel β-lactamase inhibitors is of paramount importance. Here, three novel diazabicyclooctanes (DBOs), WCK 5153, zidebactam (WCK 5107)...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Med Chem
Autori principali: Papp-Wallace, Krisztina M., Nguyen, Nhu Q., Jacobs, Michael R., Bethel, Christopher R., Barnes, Melissa D., Kumar, Vijay, Bajaksouzian, Saralee, Rudin, Susan D., Rather, Philip N., Bhavsar, Satish, Ravikumar, Tadiparthi, Deshpande, Prasad K., Patil, Vijay, Yeole, Ravindra, Bhagwat, Sachin S., Patel, Mahesh V., van den Akker, Focco, Bonomo, Robert A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6131718/
https://ncbi.nlm.nih.gov/pubmed/29627985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.8b00091
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi